公开(公告)号：EP1032404A4

公开(公告)日：2002-08-28

申请号：EP98948617

申请日：1998-10-13

申请人： UNIV AUSTRALIAN

发明人： COWDEN WILLIAM B ,  PARISH CHRISTOPHER R

IPC分类号： A61K31/7024 ,  A61K31/715 ,  A61K31/737 ,  A61P3/06 ,  A61K31/70 ,  A61K31/735

CPC分类号： A61K31/7024 ,  A61K31/737

摘要： The present invention relates generally to sulfated oligosaccharides, and in particular to the use of certain sulfated oligosaccharides as agents for lowering blood levels of triglycerides such as, for example in treatment of hypertriglyceridaemia.

摘要翻译： 本发明一般涉及硫酸化低聚糖，特别是涉及某些硫酸化寡糖作为降低甘油三酯血液水平的试剂的用途，例如治疗高甘油三酯血症。

公开(公告)号：EP1024813A4

公开(公告)日：2002-08-28

申请号：EP98939988

申请日：1998-09-01

申请人： UNIV AUSTRALIAN

发明人： COWDEN WILLIAM B ,  FRANCIS DOUGLAS J ,  PARISH CHRISTOPHER R

IPC分类号： C07H3/06 ,  A61K31/702 ,  A61K31/737 ,  A61P9/00 ,  A61P9/10 ,  A61P43/00 ,  C08B37/00 ,  A61K31/70 ,  A61K31/715 ,  A61K31/735

CPC分类号： A61K31/7024 ,  A61K31/737

摘要： A method for the inhibition of vascular smooth muscle cell hyperplasia in a human or other warm-blooded animal patient in need of such treatment, comprises administration to the patient of an effective amount of at least one sulfated oligosaccharide, wherein the oligosaccharide has the general formula I:wherein R1 and R2 and each Rx represents a monosaccharide unit, all of which may be the same or different, adjacent monosaccharide units being linked by 1->2, 1->3, 1->4 and/or 1->6 glycosidic bonds andn is an integer of from 1 to 6.

摘要翻译： 在需要这种治疗的人或其他温血动物患者中抑制血管平滑肌细胞增生的方法包括向患者施用有效量的至少一种硫酸化寡糖，其中寡糖具有通式 I：其中R1和R2和每个Rx代表单糖单元，它们都可以相同或不同，相邻的单糖单元通过1-> 2,1-3，1-> 4和/或1-> 6糖苷键，n为1〜6的整数。

公开(公告)号：EP0993483A1

公开(公告)日：2000-04-19

申请号：EP98932368.8

申请日：1998-07-03

申请人： West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited

发明人： DAVIS, Stanley Stewart ,  LIN, Wu ,  BIGNOTTI, Fabio ,  FERRUTI, Paolo

IPC分类号： C08G81/00 ,  C08B37/08 ,  A61K31/735 ,  A61K9/127 ,  A61K9/50 ,  A61K9/16

CPC分类号： A61K9/5161 ,  A61K9/0034 ,  A61K9/0043 ,  A61K9/0048 ,  A61K9/1652 ,  A61K47/61 ,  C08B37/003 ,  C08G81/00

摘要： PEG-chitosan conjugates comprising chitosan and polyethylene glycol moieties or derivatives thereof which are bonded together and their use in medicine is described. In one embodiment, the conjugate comprises a chitosan moiety or a derivative thereof and a polyethylene glycol moiety or a derivative thereof which are bonded together via the amino function on the chitosan by the use of an activated chitosan species. In another embodiment, the conjugate comprises a chitosan moiety or a derivative thereof and a polyethylene glycol moiety or a derivative thereof which are bonded together, the chitosan portion of the conjugate having a molecular weight in the range of from 10 kilodalton to 1000 kilodalton.

公开(公告)号：EP0812593A1

公开(公告)日：1997-12-17

申请号：EP97101617.5

申请日：1994-03-14

申请人： SMITHKLINE BEECHAM BIOLOGICALS S.A.

发明人： Hauser, Pierre ,  Voet, Pierre ,  Slaoui, Moncef ,  Garcon-Johnson, Nathalie Marie-Josephe Claude ,  Desmons, Pierre

IPC分类号： A61K39/39 ,  A61K31/735

CPC分类号： A61K31/7024 ,  A61K31/715 ,  A61K39/39 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/55572 ,  Y02A50/401 ,  Y02A50/466 ,  A61K2300/00 ,  A61K31/70

摘要： Novel vaccine compositions comprising small particles of 3-O-deacylated monophosphoryl lipid A are provided. In particular the particle size is below 120 nm. Such vaccine compositions have superior immunological properties.

摘要翻译： 提供了包含3-O-脱酰单磷酰脂质A的小颗粒的新型疫苗组合物。 特别地，粒径小于120nm。 这样的疫苗组合物具有优异的免疫学特性。

公开(公告)号：EP0612249A4

公开(公告)日：1995-11-08

申请号：EP92924424

申请日：1992-11-10

申请人： UNIV PENNSYLVANIA

发明人： HERRMANN HOWARD C ,  BARNATHAN ELLIOT ,  WEISZ PAUL B

IPC分类号： A61K31/715 ,  A61K31/335 ,  A61K31/395 ,  A61K31/57 ,  A61K31/724 ,  A61K31/737 ,  A61K38/18 ,  A61K47/48 ,  A61L15/28 ,  A61L26/00 ,  A61L27/20 ,  A61L27/34 ,  A61L27/36 ,  A61L27/54 ,  A61L33/00 ,  A61P43/00 ,  C07K14/50 ,  C08B37/16 ,  A61K31/70 ,  A61K31/56 ,  A61K31/735

CPC分类号： B82Y5/00 ,  A61K31/335 ,  A61K31/395 ,  A61K31/57 ,  A61K31/724 ,  A61K31/737 ,  A61K35/32 ,  A61K47/6951 ,  A61L15/28 ,  A61L26/0023 ,  A61L27/20 ,  A61L27/34 ,  A61L27/3608 ,  A61L27/54 ,  A61L33/0005 ,  A61L2300/232 ,  A61L2300/414 ,  A61L2300/802 ,  C07K14/50 ,  C07K14/503 ,  C08B37/0012 ,  C08L5/16 ,  A61K2300/00

公开(公告)号：EP0431736B1

公开(公告)日：1995-01-25

申请号：EP90311141.7

申请日：1990-10-11

申请人： Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo

发明人： Ueno, Ryuji

IPC分类号： A61K31/715 ,  A61K31/72 ,  A61K31/735

CPC分类号： A61K31/715

公开(公告)号：EP0661980A4

公开(公告)日：1994-11-24

申请号：EP92918977

申请日：1992-08-21

申请人： OKLAHOMA BAPTIST MED CENTER INC

发明人： GOOD A HEATHER ,  COOPER DAVID K C ,  MALCOLM ANDREW J

IPC分类号： A61K35/12 ,  A61K35/14 ,  A61K39/00 ,  A61M1/36 ,  A61P37/00 ,  A61K31/70 ,  A01N1/00 ,  A61K31/73 ,  A61K31/735 ,  C07K1/00 ,  C12S3/02 ,  C12S3/22

CPC分类号： A61K35/14 ,  A61K39/001 ,  A61M1/3679

摘要： Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's circulation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.

公开(公告)号：EP0447171B1

公开(公告)日：1994-11-02

申请号：EP91302039.2

申请日：1991-03-12

申请人： TANABE SEIYAKU CO., LTD.

发明人： Kurita, Hironori ,  Moriya, Tamon ,  Otake, Toru ,  Mori, Haruyo ,  Morimoto, Motoko

IPC分类号： C08B37/16 ,  A61K31/735

CPC分类号： C08B37/0012

公开(公告)号：EP0477050A2

公开(公告)日：1992-03-25

申请号：EP91402275.1

申请日：1991-08-20

申请人： CHIBA FLOUR MILLING CO. LTD. ,  Soma, Gen-Ichiro ,  Mizuno, Den'Ichi

发明人： Soma, Gen-Ichiro ,  Yoshimura, Kiyoshi ,  Tsukioka, Daisuke ,  Mizuno, Den'Ichi ,  Oshima, Haruyuki Tategaoka-Danchi 2-10-513

IPC分类号： C12N1/20 ,  C12P19/04 ,  A61K31/735

CPC分类号： C12R1/425 ,  A61K35/74 ,  A61K45/05 ,  C12P19/04 ,  C12R1/01 ,  Y02A50/475 ,  Y10S514/885

摘要： Novel LPS having the following physical properties, novel bacilli providing those LPS, and novel immunity stimulators, analgesics, and antiwithdrawal agents, and novel veterinary immunity stimulators, analgesics, and antiwithdrawal agents containing LPS selected from the group consisting of those LPSs and mixtures thereof.
LPS1

Dominant molecular weight: 5,000 ± 1,000 as determined by SDS-PAGE method
Phosphorus number: 2 ± 1 / 5,000 (m.w.)
Hexosamine number: 9 ± 1 / 5,000 (m.w.)
KDO number: 2 ± 1 / 5,000 (m.w.)

LPS2

Dominant molecular weight: 6,500 ± 2,500 as determined by SDS-PAGE method
Phosphorus number: 1 to 2 / 5,000 (m.w.)
Hexosamine number: 7 ± 1 / 5,000 (m.w.)
KDO number: 1 to 2 / 5,000 (m.w.)

LPS3

Dominant molecular weight: 6,500 ± 2,500 as determined by SDS-PAGE method
Phosphorus number: 2 ± 1 / 5,000 (m.w.)
Hexosamine number: 5 ± 1 / 5,000 (m.w.)
KDO number: 2 ± 1 / 5,000 (m.w.)

公开(公告)号：EP0422497A3

公开(公告)日：1991-08-14

申请号：EP90118964.7

申请日：1990-10-04

申请人： IBI- Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. ,  MADAUS Aktiengesellschaft

发明人： Valcavi, Umberto, Prof. ,  Monterosso, Vincenzo, Dr. ,  Caponi, Roberto, Dr. ,  Bosone, Enrico, Dr. ,  Wachter, Wilfried Peter, Dr. rer. nat. ,  Szejtli, Jozsef, Prof. Dr.

IPC分类号： C08B37/16 ,  A61K31/735

CPC分类号： C08B37/0015

摘要： The invention relates to novel inclusion complexes of Silybinin with a cyclodextrin selected from the group consisting of α-, β- and γ-cyclodextrin and a suitable derivative thereof and to the method for the preparation thereof. The novel inclusion complexes of Silybinin showed a highly improved bioavailability in comparison to Silybinin which makes them particularly interesting in the treatment of various hepatotoxic conditions.